Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Completed · Phase 3 · NCT05411198
Conditions: Open-Angle Glaucoma
At a glance
- Research payments reported, 2025
- $108,599
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 74
About the trial
- Sponsor
- AbbVie
- Tested
- XEN45 (Glaucoma Gel Stent) (device)
- Dates
- Started 2022-07-22; completion 2026-02-04
- Results posted
- Not yet
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 participants aged 45 years or older with open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United States. All participants will receive XEN45 implanted using the ab e…
From ClinicalTrials.gov, last updated 2026-02-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $108,599 in research payments for this study in 2025 (49 payments).
Products named: Xen Glaucoma Treatment System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Bryant J. Lum, M.D. Ophthalmology · Ventura, CA
- Michael C. Stiles, M.D. Ophthalmology · Overland Park, KS
- Mona A. Kaleem, MD Ophthalmology · Baltimore, MD
- Scott D. Piette, DO Ophthalmology · East Lansing, MI
- Erin G. Sieck, MD Ophthalmology · Saint Louis, MO
- Michael J. Endl II, MD Ophthalmology · Amherst, NY
- Joseph F. Panarelli, M.D. Ophthalmology · New York, NY
- Steven R. Sarkisian JR., MD Ophthalmology · Oklahoma City, OK
- Mark J. Gallardo, M.D. Ophthalmology · El Paso, TX
- Shivani S. Kamat, M.D. Ophthalmology · Dallas, TX
- Patrick Kaszubski Ophthalmology · Falls Church, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Migs Consulting LLC $26,216
- Washington University $17,504
- El PAso Eye Surgeons PA $17,018
- New Vision Eye Center LLC $12,885
- The University of Texas $8,925
- The Johns Hopkins University $6,986
- New York University $6,950
- Grene Vision Group LLC $4,703
- Lum Eye and Vision Center $3,369
- Northern Virginia Ophthalmology Associates $2,547
- Fichte Endl and Elmer Eye Surgery $1,496
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.